A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Part 1: Dose Escalation

Part 2: Expansion Cohort The study may be amended in the future to include expansion cohorts in selected tumor types to further evaluate extended safety of IMC-002 at recommended Phase 2 dose in that tumor type. Sample size in the Dose Expansion part will be determined when the study is amended to include the expansion cohorts.

Inclusion criteria

Subjects are eligible to be included in the study only if all of the following criteria apply:

• Signed informed consent form (ICF)
• Adult (18 years or older)
• Histologically or cytologically proven metastatic or locally advanced solid tumors and relapsed or refractory lymphomas, for which no standard therapy known to prolong survival exists or have relapsed/refractory/PD following the last line of treatment
• Solid tumors must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Lymphomas must have at least 1 measurable lesion according to the Lugano criteria with the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) modification
• Availability of tumor archival material or fresh biopsies for measurement of CD47
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening and an estimated life expectancy of at least 3 months
• Adequate hematologic function, hepatic function, and renal function

Exclusion criteria

Subjects are excluded from the study if any of the following criteria apply:

• Treatment with nonpermitted drugs (within 28 days before Day 1).
• Prior treatment with a CD47 or SIRPα targeting agent
• Concurrent anticancer treatments within 28 days before Day 1/first study treatment administration
• Major surgery or significant traumatic injury within 6 weeks prior to Screening or planned major surgery during the study period
• Previous malignant disease other than the target malignancy for this study, except adequately treated Stage I or II cancers from which the subject is currently in complete remission per the Investigator's clinical judgment
• Primary central nervous system (CNS) disease or leptomeningeal disease; known CNS metastases unless treated
• Comorbidities/medical history of any significant diseases that in the judgment of the Investigator would make the subject inappropriate for this study
• Active infection requiring systemic therapy within 14 days before Day 1
• Persisting toxicities Grade > 1 NCI-CTCAE Version 5.0 related to prior anticancer treatment
• Pregnant or lactating